Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
PaperCitations, authors & open-access status
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,101 citations, 2015 year and green oa status.
1,101
Citations
2015
Year
green
OA Status